News and Announcements
Cellmid Ltd – European Patent Allowed for Treating Vascular Occlusive Disease
- Published January 21, 2013 1:58PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Patent for the use of anti-midkine agents to prevent and treat blood vessel obstruction allowed in Europe
- Further IP protection for Cellmid in cardiovascular diseases and in midkine inhibitors
- Composition of matter for siRNA molecules targeting midkine also covered
SYDNEY, 21 January 2013: Cellmid Limited (ASX: CDY) advises that the European Patent Office (EPO) has issued a Rule 71(3) Communication indicating that it intends to grant Cellmid’s patent application 06746805.8 entitled “Pharmaceutical composition for vascular occlusive disease”. The application was filled in May 2006 and the patent is expected to expire in 2026.
To read a full ASX announcement, please download a document below.